FDA calendar and trial changes: week to 19 November 2026
Week to 19 Nov 2026: 5 FDA calendar events in the next 60 days, 19 clinical trial record changes on ClinicalTrials.gov. Every item links to its source.
On the FDA calendar, next 60 days
| Date as reported | Drug / company | Event | Evidence |
|---|---|---|---|
| 30 Nov 2026 | bezuclastinibCogent Biosciences, Inc. (COGT) | PDUFA dateGIST | Open original source |
| 22 Dec 2026 | LorundrostatMineralys Therapeutics Inc. (MLYS) | PDUFA datehypertension in combination with other antihypertensive drugs | Open original source |
| 22 Dec 2026 | LorundrostatMineralys Therapeutics Inc. (MLYS) | PDUFA datetreatment of hypertension in combination with other antihypertensive drugs | Open original source |
| 30 Dec 2026 | bezuclastinibCogent Biosciences, Inc. (COGT) | PDUFA dateNonAdvSM | Open original source |
| 30 Dec 2026 | bezuclastinibCogent Biosciences, Inc. (COGT) | PDUFA dateNonAdvSM | Open original source |
Trial record changes this week
NCT06775379 · Xenon Pharmaceuticals Inc. (XENE)
Recruitment status changed
Before: Active not recruiting. After: Terminated.
Primary completion date changed
Before: Oct 2026. After: 28 Oct 2026.
Participant count changed
Before: 450 participants (planned). After: 357 participants (actual).
Participant count type changed
Before: Estimated. After: Actual.
Completion date type changed
Before: Estimated. After: Actual.
NCT02227251 · Karyopharm Therapeutics Inc (KPTI)
Recruitment status changed
Before: Active not recruiting. After: Terminated.
Primary completion date changed
Before: Dec 2026. After: 2 Jun 2026.
Participant count changed
Before: 244 participants (planned). After: 279 participants (actual).
Participant count type changed
Before: Estimated. After: Actual.
Completion date type changed
Before: Estimated. After: Actual.
NCT07578558 · ImmunityBio, Inc. (IBRX)
Recruitment status changed
Before: Not yet recruiting. After: Withdrawn.
Participant count changed
Before: 50 participants (planned). After: 0 participants (actual).
Participant count type changed
Before: Estimated. After: Actual.
NCT06989359 · ADARx Pharmaceuticals, Inc. (ADRX)
Primary completion date changed
Before: 31 Dec 2028. After: 30 Apr 2030.
Planned enrollment increased by 40 participants
Before: 45 participants (planned). After: 85 participants (planned).
Main study measure wording changed
Compare the two versions on the trial page.
NCT07142811 · Vir Biotechnology, Inc. (VIR)
Primary completion date changed
Before: Nov 2026. After: Mar 2029.
NCT02736656 · Supernus Pharmaceuticals, Inc. (SUPN)
Primary completion date changed
Before: Sep 2026. After: Dec 2026.
NCT07491445 · Revolution Medicines, Inc. (RVMD)
Primary completion date changed
Before: Jun 2028. After: Apr 2028.
Main study measure wording changed
Compare the two versions on the trial page.
NCT07402876 · Aldeyra Therapeutics, Inc. (ALDX)
Primary completion date changed
Before: Dec 2026. After: Dec 2029.
NCT07425392 · Vaxcyte, Inc. (PCVX)
Primary completion date changed
Before: Mar 2027. After: 25 Oct 2026.
Recruitment status changed
Before: Active not recruiting. After: Completed.
Completion date type changed
Before: Estimated. After: Actual.
NCT07365826 · Vaxcyte, Inc. (PCVX)
Primary completion date changed
Before: Mar 2027. After: 21 Oct 2026.
Recruitment status changed
Before: Active not recruiting. After: Completed.
Completion date type changed
Before: Estimated. After: Actual.
NCT07020923 · Vera Therapeutics, Inc. (VERA)
Primary completion date changed
Before: Sep 2026. After: 22 Sep 2026.
Completion date type changed
Before: Estimated. After: Actual.
NCT06772597 · Rhythm Pharmaceuticals, Inc. (RYTM)
Primary completion date changed
Before: 31 Oct 2026. After: 3 Nov 2026.
Completion date type changed
Before: Estimated. After: Actual.
Showing 12 of 19 recorded updates. Search all tracked trials · Read the latest monthly report